Hydrogen Nanoparticles Protect Brain After Stroke in Breakthrough Study
- Authors
- Yuanman Yu, Mingjian Fan, Gaoyi Wu, Yongcheng Li, Chao Xia, Wenjiang Ding, Guanglin Li, Qianjun He, Wei Tang, Changsheng Liu
- Journal
- Science Advances
- Year
- 2026
- DOI
- 10.1126/sciadv.aea3355
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Ischemic Stroke
- Body System
- Nervous System
TL;DR
A vessel-anchored nanoparticle system generated sustained hydrogen at the blood–brain barrier, improving neurovascular repair and functional recovery after ischemic stroke in a preclinical model.
Key Finding
Vessel-anchored hydrogen-producing nanoparticles delivered hydrogen across the blood-brain barrier and produced superior functional recovery in stroke-treated mice compared to edaravone, a standard stroke therapy.
Summary
Researchers developed special nanoparticles (tiny engineered particles) that stick to blood vessels in the brain and produce hydrogen gas when exposed to fluid. In a mouse model of stroke, these particles released hydrogen across the blood-brain barrier (the protective layer that controls what enters the brain), where the hydrogen reduced inflammation and oxidative stress (cellular damage from unstable molecules). The treatment promoted the growth of new blood vessels and nerve cells, leading to better recovery than a standard stroke medication.
Practical Takeaway
This is early-stage research in mice only, so it cannot yet be applied to human stroke treatment. The study suggests that hydrogen gas may have protective effects in stroke through anti-inflammatory mechanisms, but much more research—including human trials—would be needed before this approach could be considered for clinical use. The novel delivery method (anchoring at blood vessels rather than penetrating brain tissue) is scientifically interesting but remains experimental.
Abstract
Ischemic stroke followed by reperfusion urgently requires safe and efficient cytoprotective strategies, a need still unmet by current pharmacotherapies. Nanotechnology holds promise for improved drug delivery to the brain, yet the efficacy of nanomaterials crossing the blood-brain barrier (BBB) is quite limited, and long-term intracranial retention of nanomaterials may provoke neurotoxicity. Leveraging the anti-inflammatory, BBB-crossing, and biosafe properties of hydrogen (H2), we develop an inflamed vessel-targeted/anchored H2-producing system by modifying ZrSi2 nanoparticles with a P-selectin-binding peptide (ZSNP), mimicking P-selectin/P-selectin glycoprotein ligand-mediated innate immune recruitment. Rather than relying on nanoparticle penetration into the brain parenchyma, this design enables ZSNP to anchor at the BBB vasculature, where it locally and continuously generates H2 via hydrolysis. The released H2 traverses the BBB, exerting cytoprotection through antioxidant and immunomodulatory mechanisms that coordinate multicellular recovery processes. Furthermore, ZSNP promotes microglia-mediated angiogenesis and neurogenesis, guides axonal projections along neovascular trajectories, and facilitates microglia-neuron interaction via the noncanonical Wnt/Ca2+ pathway. This reconstruction of the neurovascular network supports the reintegration of functional neural circuits, leading to structural and functional recovery that surpasses the effects of edaravone. By enabling sustained H2 release at the BBB interface without requiring nanoparticle intracranial accumulation, this strategy represents a promising and low-burden neuroprotective approach for ischemic stroke.